Cardiolipin - IgA antibody

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by antiphospholipid antibodies in the blood. These antibodies target phospholipid molecules, such as cardiolipin, leading to an increased risk of pregnancy complications and thrombotic events, such as deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction. Unlike IgG or IgM antibodies, IgA antibodies are primarily found in mucosal tissues (such as the gut and respiratory tract) but can circulate in the blood during autoimmune activity, causing chronic or persistent clotting risks.

The Cardiolipin - IgA antibody test specifically detects immunoglobulin A (IgA) antibodies against cardiolipin. While IgM and IgG antibodies are more commonly tested, IgA antibodies can also play a significant role in APS and are particularly useful in cases where IgM and IgG antibodies are absent but clinical suspicion remains.

The test is typically recommended for individuals with a history of unexplained blood clots, recurrent miscarriages, or those with symptoms suggestive of antiphospholipid syndrome. The Anti Cardiolipin IgA Antibody test is not reliable alone for monitoring treatment effectiveness, as anti-cardiolipin levels fluctuate significantly and should not be used as the sole treatment monitoring marker for autoimmune diseases like APS and systemic lupus erythematosus (SLE).

A positive test result does not always indicate the presence of antiphospholipid syndrome, as these antibodies can be found in other conditions, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, as well as in some healthy people. Hence, the Cardiolipin - IgA antibody test results should be interpreted in conjunction with other tests and clinical findings to confirm a diagnosis.

Anti-cardiolipin antibody levels can fluctuate, and a single test may not provide a definitive diagnosis. Hence, the Anti Cardiolipin IgA Antibody test must be repeated ≥12 weeks later to confirm persistence per APS diagnostic criteria, along with correlation to clinical events (thrombosis or pregnancy morbidity), and it is not intended for routine monitoring.

No special preparation is needed before the Cardiolipin - IgA antibody test. However, inform the doctor about all the medications or supplements being taken, as a few of them may affect the test results, potentially requiring dosage adjustments or temporary discontinuation before the test.

Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results. Always consult a doctor for a proper understanding of the test results. The insights from this test help the doctor tailor an appropriate treatment plan.

Please note: This is an outsourced test. The sample for this test is collected by TATA 1MG and processed at a NABL accredited partnered lab.